The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
BACKGROUND
PARP inhibition is an exciting new anticancer strategy. Olaparib has recently obtained a first in class license in Europe and the USA for the treatment of relapsed BRCA-mutant ovarian cancer.


METHODS
We review the key preclinical and clinical data surrounding its use in the maintenance setting. Expert commentary: We also consider the market profile, regulatory issues surrounding the agent and offer a five year speculative viewpoint of its future development in ovarian cancer.
a Edinburgh Cancer Centre , Western General Hospital , Edinburgh , UK.
Rachel
R
Nirsimloo
b MRC IGMM , University of Edinburgh Cancer Research UK Centre , Edinburgh , UK.
Charlie
C
Gourley
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010793:Phthalazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib
BRCA; Ovarian cancer; PARP inhibitor; homologous recombination; maintenance; olaparib; synthetic lethality